Protocol Ledger

NCT05256381 · Phase II · TERMINATED

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Interventional Phase II clinical trial protocol NCT05256381 sponsored by SOTIO Biotech AG in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-21 Enrollment: 166 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05256381
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)166 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05256381
Protocol FieldVerified Registry Value
NCT IdentifierNCT05256381
Consolidated Lead SponsorSOTIO Biotech AG
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment166 participants (ACTUAL)
Registered Start Date2022-06-21
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05256381
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI